Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
08:18pm, Monday, 06'th Nov 2023
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics
07:33pm, Monday, 06'th Nov 2023
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
06:47pm, Monday, 06'th Nov 2023
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.74 per share a year ago.
Halozyme To Report Third Quarter 2023 Financial and Operating Results
06:35pm, Monday, 30'th Oct 2023
SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, Nove
Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune
08:47am, Friday, 27'th Oct 2023
The quest to uncover the next big success story is an ongoing pursuit for investors. Three companies are captivating exemplars of success for those seeking to turn a modest investment into a financial
7 Sleeper Stocks That Should Be on Every Investor's Radar This Fall
02:51pm, Saturday, 23'rd Sep 2023
Targeting sleeper stocks to buy might just be the strategy investors need in the current landscape. With numerous tech-centric stocks soaring to unprecedented heights, it's thrilling to watch their tr
Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA Setback
05:59pm, Tuesday, 12'th Sep 2023
Halozyme Therapeutics, based in San Diego, has developed ENHANZE technology based around its proprietary enzyme, rHuPH20. The enzyme makes it possible for many intravenously administered drugs to be a
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
11:18am, Tuesday, 05'th Sep 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
01:42pm, Wednesday, 09'th Aug 2023
Halozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected second-quarter 2023 results, boosted by collaboration and royalty revenues. Management raises its 2023 guidance
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
10:41pm, Tuesday, 08'th Aug 2023
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall St
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
06:56pm, Tuesday, 08'th Aug 2023
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.53 per share a year ago.
Halozyme Therapeutics (HALO) Soars 5.4%: Is Further Upside Left in the Stock?
06:49am, Tuesday, 18'th Jul 2023
Halozyme Therapeutics (HALO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt
Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study
12:39pm, Friday, 14'th Jul 2023
Halozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology meets goals.
Halozyme: Inflection Point With argenx's Vyvgart SC Approval (Reiterating Buy)
06:24am, Wednesday, 05'th Jul 2023
argenx's Vyvgart Hytrulo, a game-changer with its 1-minute SC formulation, opens a new revenue stream for Halozyme with sales expected to surpass $10Bn. Despite past headwinds, Vyvgart's SC approval a
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
11:19am, Tuesday, 27'th Jun 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
